Mirum Pharmaceuticals Future Growth
Future criteria checks 5/6
Mirum Pharmaceuticals is forecast to grow earnings and revenue by 65.6% and 25.2% per annum respectively. EPS is expected to grow by 67.9% per annum. Return on equity is forecast to be 19.7% in 3 years.
Key information
65.6%
Earnings growth rate
67.9%
EPS growth rate
| Biotechs earnings growth | 23.2% |
| Revenue growth rate | 25.2% |
| Future return on equity | 19.7% |
| Analyst coverage | Good |
| Last updated | 18 Apr 2024 |
Recent future growth updates
Recent updates
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Apr 22Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mar 05There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price
Dec 26
What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You
Jun 10Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts
Apr 18Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU
Oct 14Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
Aug 17Mirum Pharmaceuticals announces $80M stock offering
Aug 09Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
May 27Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?
Apr 22Mirum Pharmaceuticals Gets The 'Thumbs Up'
Dec 16Need To Know: Analysts Just Made A Substantial Cut To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates
Nov 25Mirum And Maralixibat In Pediatric Cholestasis: The Differentiation
Aug 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 527 | 81 | 69 | 207 | 5 |
| 12/31/2025 | 418 | 19 | 20 | 27 | 9 |
| 12/31/2024 | 316 | -59 | -24 | -18 | 10 |
| 12/31/2023 | 186 | -163 | -91 | -71 | N/A |
| 9/30/2023 | 145 | -164 | -104 | -89 | N/A |
| 6/30/2023 | 116 | -176 | -112 | -96 | N/A |
| 3/31/2023 | 96 | -129 | -115 | -114 | N/A |
| 12/31/2022 | 77 | -136 | -120 | -120 | N/A |
| 9/30/2022 | 52 | -42 | -138 | -119 | N/A |
| 6/30/2022 | 39 | -53 | -146 | -127 | N/A |
| 3/31/2022 | 32 | -70 | -166 | -147 | N/A |
| 12/31/2021 | 19 | -84 | -152 | -133 | N/A |
| 9/30/2021 | 16 | -179 | -136 | -136 | N/A |
| 6/30/2021 | 11 | -153 | -119 | -119 | N/A |
| 3/31/2021 | N/A | -132 | -96 | -96 | N/A |
| 12/31/2020 | N/A | -103 | -89 | -89 | N/A |
| 9/30/2020 | N/A | -84 | -67 | -66 | N/A |
| 6/30/2020 | N/A | -78 | -65 | -64 | N/A |
| 3/31/2020 | N/A | -68 | -56 | -55 | N/A |
| 12/31/2019 | N/A | -53 | -40 | -39 | N/A |
| 9/30/2019 | N/A | -61 | -38 | -26 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MIRM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: MIRM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MIRM is expected to become profitable in the next 3 years.
Revenue vs Market: MIRM's revenue (25.2% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: MIRM's revenue (25.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MIRM's Return on Equity is forecast to be low in 3 years time (19.7%).